FDA cracks down on 1,000 illegal online medicine sellers
(Reuters) — The FDA said yesterday it had sent warning letters and seized potentially dangerous, unapproved medicines and medical devices from more than 1,050 websites globally.
Inspectors from the FDA and other federal agencies screened and seized illegal drugs and medical devices received through international mail facilities in Chicago, Miami and New York, the FDA said in a statement.
The health regulator said it sent warning letters to operators of nearly 400 websites and to 9 firms distributing unapproved medical devices online.
The prescription drugs targeted included some purported to be the generic versions of ...
Source: Mass Device - June 19, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Business/Financial News Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news
Cipla expects to double sales of respiratory drugs by 2020
Cipla is building up its respiratory drug portfolio. Seroflo, a generic version of GSK Plc's inhaler Advair, is one of its biggest bets in that segment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 17, 2015 Category: Pharmaceuticals Source Type: news
Adding a LAMA to Salmeterol/Fluticasone Improves COPD Lung FunctionAdding a LAMA to Salmeterol/Fluticasone Improves COPD Lung Function
Adding a once-a-day long-acting muscarinic antagonist (LAMA) to salmeterol/fluticasone propionate (SAL/FP) improves outcomes in chronic obstructive pulmonary disease (COPD), according to a report from Australia and New Zealand. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 8, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
GSK sees little prospect of U.S. generic Advair in 2016
LONDON (Reuters) - After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics - but not just yet. (Source: Reuters: Health)
Source: Reuters: Health - May 6, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
How Medicare contributed to GSK's top line (Hint: Advair)
Medicare spent $2.26 billion on GlaxoSmithKline's (NYSE: GSK) asthma drug, Advair Diskus, in 2013, making it the second-costliest drug for the government payer in 2013.
More than 1.5 million beneficiaries filed 6.6 million claims for the inhalable dry powder that comes in the plastic purple dispensing device. Large portions of the drug and the device are produced in Zebulon.
For the first time, Medicare publicly released detailed information on the prescription drugs that health providers prescribed… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 1, 2015 Category: American Health Authors: Jason deBruyn Source Type: news
Lupin and Celon Pharma partner for generic version of GSK’s Advair Diskus
India-based drugmaker Lupin has signed an agreement with Polish biopharmaceutical firm Celon Pharma to develop a fluticasone / salmeterol dry powder inhaler (DPI). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 18, 2015 Category: Pharmaceuticals Source Type: news
First Generic Version of Advair Diskus Approved for Asthma, COPD
(Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 11, 2014 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, Asthma, FDA Approvals, Source Type: news
FDA Approves First Generic Version of Advair for Asthma, COPD
Medication approved to treat children aged 4 or older with asthma, adults with asthma or COPD (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 11, 2014 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Internal Medicine, Allergy, Pediatrics, Pharmacy, Pulmonology, Institutional, Source Type: news
Mylan to start Phase III trial of generic Advair Diskus, insulin analogue to Lantus
Global generic and specialty pharmaceuticals company Mylan is set to start a Phase III clinical trial of its generic version of GlaxoSmithKline's (GSK) Advair Diskus and its insulin analogue to Sanofi's Lantus. (Source: Drug Development Technology)
Source: Drug Development Technology - September 16, 2014 Category: Pharmaceuticals Source Type: news
Novartis data show once-daily Ultibro® Breezhaler® is superior in COPD
Novartis presented new data that demonstrated once-daily Ultibro® Breezhaler® (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and improving lung function compared to twice-daily Seretide®Accuhaler®* (salmeterol/fluticasone (SFC)), in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 8, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News Respiratory copd exacerbation indacaterol/glycopyrronium bromide Latest News lung function Source Type: news
Cipla introduces Serroflo for respiratory treatment in Germany and Sweden
India-based Cipla has introduced Serroflo (salmeterol/fluticasone MDI) in Germany and Sweden to treat patients suffering from asthma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 2, 2014 Category: Pharmaceuticals Source Type: news
Cipla Ltd launches copy of GSK's top asthma drug in Germany, Sweden
Cipla Ltd launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 1, 2014 Category: Pharmaceuticals Source Type: news
India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden
MUMBAI (Reuters) - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product. (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
China Bribery Probe, Dismal Advair Sales Leave Glaxo Shares Gasping
British drug giant GlaxoSmithkline (GSK) this morning slashed its earnings expectations for the year, citing currency fluctuations and deteriorating sales of its respiratory drug Advair, particularly in light of moves in the U.S. by insurers unwilling to pay for the more expensive brand name. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 23, 2014 Category: Pharmaceuticals Authors: Bruce Japsen Source Type: news
GSK agrees to pay $105m in asthma and antidepressant drugs settlement
GlaxoSmithKline (GSK) has agreed to pay $105m to settle allegations that it unlawfully promoted its asthma drug Advair, and antidepressants Paxil and Wellbutrin. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 4, 2014 Category: Pharmaceuticals Source Type: news
